Tech Company Financing Transactions
Immuneering Funding Round
On 1/23/2020, Immuneering landed $3 million in Series A funding from Boxcar PMJ and private investors.
Transaction Overview
Company Name
Announced On
1/23/2020
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series A
Investors
Boxcar PMJ (Lead Investor) (Joseph Kekst)
Proceeds Purpose
Proceeds from the financing will be used to advance Immuneering's programs towards the clinic in cancer cachexia, next-generation KRAS inhibition, and the RAF-MEK pathway, while further developing the company's Disease Cancelling Technology and computational platforms.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Zeskind
Chief Medical Officer
Scott Barrett
Chief Scientific Officer
Brett Hall
Co-Founder
Robert Carpenter
Vice President
Jason Funt
Vice President
Peter King
Vice President
Sarah Kolitz
Vice President
Andrew Lysaght
VP - Bus. Development
Rebecca Kusko
VP - R & D
Kevin Fowler
VP - R & D
Howard Kaufman
Browse more venture capital transactions:
Prev: 1/23/2020: Outlier.ai venture capital transaction
Next: 1/23/2020: Socially Determined venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs